Oramed Pharmaceuticals Inc. (ORMP.TA)
ILA 879.9
(4.22%)
ILA 879.9
(4.22%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -142.66 Million USD | -92.72% |
| 2021 | -74.02 Million USD | -87.96% |
| 2020 | -39.38 Million USD | 23.72% |
| 2019 | -51.63 Million USD | -6.09% |
| 2018 | -48.66 Million USD | -26.04% |
| 2017 | -38.61 Million USD | -2.01% |
| 2016 | -37.85 Million USD | -29.52% |
| 2015 | -29.22 Million USD | -38.74% |
| 2014 | -21.06 Million USD | -35.31% |
| 2013 | -15.56 Million USD | -35.18% |
| 2012 | -11.51 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q3 | -10.84 Million USD | 21.9% |
| 2023 Q1 | -18.64 Million USD | 45.52% |
| 2023 Q2 | -13.88 Million USD | 25.49% |
| 2022 Q3 | -29.12 Million USD | 26.93% |
| 2022 FY | - USD | -92.72% |
| 2022 Q1 | -35.95 Million USD | 37.11% |
| 2022 Q2 | -39.86 Million USD | -10.87% |
| 2022 Q4 | -34.21 Million USD | -17.46% |
| 2021 Q3 | -23.67 Million USD | -44.34% |
| 2021 Q4 | -57.17 Million USD | -141.48% |
| 2021 Q1 | -16.03 Million USD | 16.72% |
| 2021 Q2 | -16.4 Million ILA | -2.32% |
| 2021 FY | - USD | -87.96% |
| 2020 Q3 | -10.11 Million USD | -26.82% |
| 2020 Q2 | -7.97 Million USD | 43.07% |
| 2020 Q4 | -19.25 Million USD | -90.37% |
| 2020 Q1 | -14 Million USD | -66.05% |
| 2020 FY | - USD | 23.72% |
| 2019 Q1 | -12.92 Million USD | 25.05% |
| 2019 Q2 | -14.78 Million USD | -14.39% |
| 2019 FY | - USD | -6.09% |
| 2019 Q4 | -8.43 Million USD | -1.96% |
| 2019 Q3 | -8.27 Million USD | 44.03% |
| 2018 Q4 | -17.24 Million USD | -51.94% |
| 2018 Q1 | -10.81 Million USD | -13.3% |
| 2018 Q3 | -11.34 Million USD | 29.77% |
| 2018 Q2 | -16.16 Million USD | -49.46% |
| 2018 FY | - USD | -26.04% |
| 2017 Q2 | -7.62 Million USD | 37.78% |
| 2017 Q4 | -9.54 Million USD | 6.63% |
| 2017 FY | - USD | -2.01% |
| 2017 Q1 | -12.24 Million USD | -33.37% |
| 2017 Q3 | -10.22 Million USD | -34.13% |
| 2016 Q3 | -13.36 Million USD | -64.38% |
| 2016 FY | - USD | -29.52% |
| 2016 Q4 | -9.18 Million USD | 31.28% |
| 2016 Q2 | -8.12 Million USD | -8.84% |
| 2016 Q1 | -7.46 Million USD | 21.22% |
| 2015 Q2 | -6.32 Million USD | 5.04% |
| 2015 Q1 | -6.66 Million USD | 10.09% |
| 2015 FY | - USD | -38.74% |
| 2015 Q4 | -9.48 Million USD | -10.97% |
| 2015 Q3 | -8.54 Million USD | -35.09% |
| 2014 Q2 | -6.6 Million USD | -59.83% |
| 2014 Q1 | -4.13 Million USD | -0.56% |
| 2014 Q3 | -5.88 Million USD | 10.96% |
| 2014 Q4 | -7.4 Million USD | -25.97% |
| 2014 FY | - USD | -35.31% |
| 2013 FY | - USD | -35.18% |
| 2013 Q1 | -4.67 Million USD | -68.05% |
| 2013 Q3 | -3.53 Million USD | 28.19% |
| 2013 Q4 | -4.1 Million USD | -16.22% |
| 2013 Q2 | -4.92 Million USD | -5.33% |
| 2012 Q3 | -3.74 Million USD | 0.0% |
| 2012 Q4 | -2.78 Million USD | 25.78% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|